[14] demonstrated the presence of active gilteritinib in the CSF and also showed that CSF from patients on gilteritinib therapy cultured with an AML cell line harboring a FLT3‐ITD had an anti‐leukemic effect and reduced proliferation in vitro [14]. Here, FLT3 is linked to acute myeloid leukemia.